 NEW YORK, June 9, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health NIH sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimers disease AD. To date, the Company has now dosed 58 of its target 100 patients. 